skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

View Informa Pharma Intelligence's Q2 2021 Pulse Report

Since the first COVID-19 vaccine was authorized for emergency use in December 2020, over 100 million Americans and counting have been fully vaccinated. Public health experts have since shifted strategy away from herd immunity to ongoing management of the virus by closely tracking hot spots and variants as they emerge, while continuing to develop variant-specific vaccines and therapeutics. As nearly a quarter of Americans are still hesitant to take any of the vaccines available based on Phase III clinical trial data, including those manufactured by Pfizer-BioNTech, Moderna and Johnson & Johnson, education and dissemination of clear and accurate information on the safety and efficacy of these vaccines will be critical to reducing the virus to a managed state.

Download the report

The goal of our second Clinical Trials & the COVID-19 Vaccine Pulse Report is to uncover who is still hesitant to take a vaccine, and what public health experts from pharma to the U.S. government can do to turn the tide.
pulse-2021

Read also

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: